OVERVIEW
Brain tumors are a heterogenous group of neoplasms with varied management strategies and outcomes. This tumor board will present cases and discuss emerging research to help neuro-oncologists better identify relevant molecular markers and appropriate treatment options for subgroups of malignant glioma, and incorporate the latest developments in therapy for patients with high-grade glioma.
GOAL
Through a challenging case presentation delivered in a tumor board format, this educational activity offers an opportunity for providers to assess and improve their knowledge, skills, and attitudes regarding care of patients with high-grade gliomas.
TARGET AUDIENCE
This activity is designed for neuro-oncologists, neurosurgeons, radiation oncologists, and other medical oncologists who research, identify, and treat patients with high-grade gliomas. No prerequisites required.
CME INFORMATION
Accreditation Statement — The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement — The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
In order to earn credit for this activity, participants must: complete the pre-test assessment, review the case presentation, and complete the CME test and evaluation.
Activity Format — On-demand forum for discussion, debate, and dialogue in regard to optimal treatment for high-grade gliomas.
Estimated time to complete activity: 15 minutes.
Release date: June 30, 2010. Expiration date: June 30, 2012.
FULL DISCLOSURE POLICY AFFECTING CME ACTIVITIES
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine to require the disclosure of the existence of any relevant financial interest or any other relationship a faculty member or a provider has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Steering Committee and Participating Faculty reported the following:
Steering Committee
Alessandro Olivi, MD (Co-Chair)
Professor of Neurosurgery and Oncology
Johns Hopkins University School of Medicine
Baltimore, Maryland
Dr Olivi reports having no relationships with commercial interests related to this activity.
Allen K. Sills, MD, FACS (Co-Chair)
Associate Professor
Department of Neurological Surgery
Vanderbilt University School of Medicine
Nashville, Tennessee
Dr Sills reports having no relationships with commercial interests related to this activity.
Jaishri Blakeley, MD
Assistant Professor of Neurology, Oncology, and Neurosurgery
Johns Hopkins University School of Medicine
Baltimore, Maryland
Dr Blakeley reports having no relationships with commercial interests related to this activity.
Participating Faculty
L. Burt Nabors, MD
Professor, Department of Neurology
Director, Division of Neuro-oncology
The University of Alabama at Birmingham
Birmingham, Alabama
Dr Nabors reports having no relationships with commercial interests related to this activity.
Volker W. Stieber, MD
Medical Director Stereotactic Radiation Oncology
Derrick L. Davis Forsyth Regional Cancer Center
Winston-Salem, North Carolina
Dr Stieber reports having no relationships with commercial interests related to this activity.
Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution that receives the grant, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).
OFF-LABEL PRODUCT DISCUSSION
The following faculty members have disclosed that their content will reference unlabeled/unapproved use of drugs or products:
Dr Blakeley—CPT-11, gefitinib, talampanel.
DISCLAIMER STATEMENT
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.
INTERNET CME POLICY
The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals, and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based activity. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine’s CME activity. CME collects only the information necessary to provide you with the services that you request.
TUMOR BOARD ACTIVITY
Instructions
The following is an interactive tumor board designed to help you solve treatment challenges through a case presentation. It consists of 3 sections: a pre-test assessment; a challenging case presentation, on which you are encouraged to comment; and a CME post-test and evaluation. All 3 sections must be completed to receive CME credit.
Pre-Test
Left Temporal Tumor, 41-Year-Old Female
Post-Test
